Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1401 (HF10) in solid tumors with superficial lesions
NCT02428036Phase 1Completed
- Sponsor
- Takara Bio Inc.
- Start
- Jun 2015
- Primary completion
- Oct 2016
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of canerpaturev in solid tumor (2 cohorts), sponsored by Takara Bio Inc. Primary endpoint: Safety and tolerability (CTCAE version 4.0). Started Jun 2015; status: completed.
02
Drugs
canerpaturev
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02428036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428036.